The Importance of DHEA-S Levels in Cushing’s Syndrome; Is There a Cut-off Value in the Differential Diagnosis?

Abstract

The purpose of this study was to determine possible cut-off levels of basal DHEA-S percentile rank in the differential diagnosis of patients with Cushing’s syndrome (CS) with ACTH levels in the gray zone and normal DHEA-S levels.

In this retrospective study including 623 pathologically confirmed CS, the DHEA-S percentile rank was calculated in 389 patients with DHEA-S levels within reference interval. The patients were classified as group 1 (n=265 Cushing’s disease; CD), group 2 (n=104 adrenal CS) and group 3 (n=20 ectopic ACTH syndrome).ROC-curve analyses were used to calculate the optimal cut-off level of DHEA-S percentile rank in the reference interval in the differential diagnosis of CS, and the effectiveness of this cut-off level in the identification of the accurate etiology of CS was assessed in patients who were in gray zone according to their ACTH levels.

The DHEA-S percentile rank in the reference interval were significantly lower in group 2 compared to the other two groups (p<0.001), while group 1 and group 3 had similar levels. The optimal cut-off level of DHEA-S percentile rank in the reference interval providing differential diagnosis between group 1 and group 2 was calculated as 19.5th percentile (80.8% sensitivity, 81.5% specificity) and the level demonstrated the accurate etiology in 100% of CD and 76% of adrenal CS patients who were in the gray zone.

This study showed that the cut-off value of DHEA-S level less than 20% of the reference interval could be used for differential diagnosis of CD and adrenal CS with high sensitivity and specificity, and it should be taken into the initial evaluation.

Key words

Cushing’s disease - adrenal Cushing’s syndrome - ectopic ACTH syndrome - dehydroepiandrosterone-sulfate - DHEA-S cut-off - differential diagnosis

Publikationsverlauf

Eingereicht: 09. Januar 2022

Angenommen nach Revision: 22. Februar 2022

Artikel online veröffentlicht:
12. April 2022

• References

• 1 Orth DN. Cushing’s syndrome. N Engl J Med 1995; 332: 791-803
• 2 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 3 Arnaldi G, Angeli A, Atkinson AB. et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602
• 4 Nieman LK, Biller MB, Findling JW. et al Endocrine Society. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 2807-2831
• 5 Nieman LK. Diagnosis of Cushing’s syndrome in the modern era. Endocrinol Metab Clin North Am 2018; 47: 259-273
• 6 Lacroix A, Feelders RA, Stratakis CA. et al. Cushing’s syndrome. Lancet 2015; 386: 913-927
• 7 Newell-Price J, Trainer P, Besser GM. et al. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998; 19: 647-667
• 8 Lindsay JR, Nieman LK. Differential diagnosis and imaging in Cushing’s syndrome. Endocrinol Metab Clin N Am 2005; 34: 403-421
• 9 Parker LN, Odell WD. Control of adrenal androgen secretion. Endocr Rev 1980; 1: 392-410
• 10 Arnaldi G, Martino M. Androgens in Cushing’s syndrome. Front Horm Res 2019; 53: 77-91
• 11 Yamaji T, Ibayashi H. Plasma dehydroepiandrosterone sulfate in normal and pathological conditions. J Clin Endocrinol Metab 1969; 29: 273-278
• 12 Barbetta L, Dall’Asta C, Re T. et al. Androgen secretion in ectopic ACTH syndrome and in Cushing’s disease: modifications before and after surgery. Horm Metab Res 2001; 33: 596-601
• 13 Hong AR, Kim JH, Hong ES. et al. Limited diagnostic utility of plasma adrenocorticotropic hormone for differentiation between adrenal Cushing syndrome and Cushing disease. Endocrinol Metab (Seoul) 2015; 30: 297-304
• 14 Hauffa BP, Kaplan SL, Grumbach MM. Dissociation between plasma adrenal androgens and cortisol in Cushing’s disease and ectopic ACTH-producing tumour: relation to adrenarche. Lancet 1984; 1: 1373-1376
• 15 Cunningham SK, McKenna TJ. Dissociation of adrenal androgen and cortisol secretion in Cushing’s syndrome. Clin Endocrinol (Oxf) 1994; 41: 795-800
• 16 Yamaji T, Ishibashi M, Sekihara H. et al. Serum dehydroepiandrosterone sulfate in Cushing’s syndrome. J Clin Endocrinol Metab 1984; 59: 1164-1168
• 17 Kleiber H, Rey F, Temler E. et al. Dissociated recovery of cortisol and dehydroepiandrosterone sulphate after treatment for Cushing’s syndrome. J Endocrinol Invest 1991; 14: 489-492
• 18 McKenna TJ, Cunningham SK. The control of adrenal androgen secretion. J Endocrinol 1991; 129: 1-3
• 19 Genazzani AR, Facchinetti F, Petraglia F. et al. Correlations between plasma levels of opioid peptides and adrenal androgens in prepuberty and puberty. J Steroid Biochem 1983; 19: 891-895
• 20 Vaitukaitis IL, Dale SL, Melby JC. Role of ACTH in the secretion of dehydroepiandrosterone and its sulfate ester in man. J Clin Endocrinol Metab 1969; 29: 1443-1447
• 21 Rege J, Nakamura Y, Satoh F. et al. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J Clin Endocrinol Metab 2013; 98: 1182-1188
• 22 Horio S, Funahashi H, Mizuno S. Plasma steroid hormones in Cushing’s syndrome: their relation to cause and clinical manifestations (Author’s Transl). Nihon Naibunpi Gakkai Zasshi 1981; 57: 807-825
• 23 Valassi E, Franz H, Brue T. et al. ERCUSYN study group. Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN. Eur J Endocrinol 2017; 176: 613-624
• 24 Selek A, Cetinarslan B, Canturk Z. et al. The utility of preoperative ACTH/cortisol ratio for the diagnosis and prognosis of Cushing’s disease. J Neurosci Rural Pract 2018; 9: 106-111
• 25 Burkhardt T, Schmidt NO, Vettorazzi E. et al. DHEA(S) – a novel marker in Cushing’s disease. Acta Neurochir (Wien) 2013; 155: 479-484
• 26 Wajchenberg BL, Mendonca BB, Liberman B. et al. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1994; 15: 752-787
• 27 Nawata H, Higuchi K, Yanase T. et al. Mechanism of dissociation of cortisol and adrenal androgen secretion after removal of adrenocortical adenoma in patients with Cushing’s syndrome. Endocrinol Jpn 1985; 32: 691-700
• 28 O’Hare MJ, Nice EC, Neville AM. Regulation of androgen secretion and sulfoconjugation in the adult human adrenal cortex: studies with primary monlayer cell cultures. In: Genazzani AR, Thijssen JHH, Siiteri PK (eds). Adrenal Androgens. Raven Press; New York: 1980: 7
• 29 Kuo CH, Shih SR, Li HY. et al. Adrenocorticotropic hormone levels before treatment predict recurrence of Cushing’s disease. J Formos Med Assoc 2017; 116: 441-447
• 30 El Asmar N, Rajpal A, Selman WR. et al. The value of perioperative levels of ACTH, DHEA, and DHEA-S and tumor size in predicting recurrence of Cushing disease. J Clin Endocrinol Metab 2018; 103: 477-485